Immatics N.V. (IMTX) fair value analysis
Nasdaq · Updated 2026-10-19
IMTX price how computed
Valuation status
Reports in EURIMTX reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for IMTX until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $8.44
- Sector
- Healthcare
- 12-month range
- $6.73–$11.87
- Market cap
- $1.28B
- From 52-week high
- -28.9%
- Shares outstanding
- 152M
- Rank in Healthcare by quality score
- #102 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Immatics N.V. is a biopharmaceutical company that develops personalized cancer immunotherapies, including engineered T-cell therapies and neoantigen-based approaches. The company operates in the United States and Europe, conducting research and development activities across multiple locations to advance its therapeutic pipeline.
IMTX currently ranks #102 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $1.28B
- Revenue (TTM)
- EUR 41.7M
- Net margin
- -495.3%
- EPS (TTM)
- EUR -1.87
- Gross margin
- 100.0%
- Debt / equity
- 0.04
- Revenue growth (3-yr avg)
- 18.1%
- Shares outstanding
- 152M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 27 · oversold
- 50-day average
- $8.66
- 200-day average
- $9.71
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-16
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-23.3%)
2026-03 ▼ miss (-15.9%)
2025-12 ▲ beat (+18.1%)
2025-09 ▼ miss (-8.9%)
2025-06 ▼ miss (-88.9%)
2025-03 ▼ miss (-12.1%)
2024-12 ▲ beat (+234.3%)
2024-09 ▲ beat (+71.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 0 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $17.3
- Target vs last price
- +105.0%
What our data shows for IMTX
- Shares are trading in the lower third of their 12-month price range of $6.73–$11.87.
- The 14-day relative strength index sits at an oversold 27.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- IMTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent IMTX news
TickrTrends' derived news-sentiment signal for IMTX is currently leaning positive, computed from recent coverage.
- Immatics: 'Buy' On 1st Half 2027 Catalyst, Potential Label Expansion For Uveal Melanoma (seekingalpha.com, 2026-08-25)
What people are saying
Follow the IMTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — IMTX in the Healthcare sector has experienced a shift in its RSI zone from neutral to oversold this week according to TickrTrends' derived indicators. The stock's valuation verdict remains classified as awaiting full valuation. These technical changes reflect a movement in the stock's recent price momentum metrics over the past seven days.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for IMTX show a shift in the 50/200-day trend state this week, moving from mixed to downtrend. The stock operates within the Healthcare sector and currently carries a valuation verdict of awaiting full valuation. These technical indicators reflect the recent price action registered in IMTX's trading patterns.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is IMTX stock undervalued?
IMTX reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for IMTX until same-currency inputs are available.
What is IMTX's TickrTrends verdict?
IMTX is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does IMTX compare to other Healthcare stocks?
IMTX ranks #102 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is IMTX overbought or oversold?
IMTX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does IMTX report earnings next?
IMTX's next earnings report is scheduled for 2026-11-16, per the published earnings calendar.
Does IMTX usually beat earnings estimates?
Over its last 8 reported quarters IMTX beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about IMTX?
Of 8 analysts covering IMTX, 8 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $17.3 (+105.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.